NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 309 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $86,000 | +17.8% | 1,239 | +41.0% | 0.00% | – |
| Q1 2022 | $73,000 | +28.1% | 879 | +16.7% | 0.00% | – |
| Q4 2021 | $57,000 | -36.0% | 753 | -1.3% | 0.00% | -100.0% |
| Q3 2021 | $89,000 | -66.7% | 763 | -36.7% | 0.00% | -50.0% |
| Q2 2021 | $267,000 | +468.1% | 1,205 | +240.4% | 0.00% | +100.0% |
| Q1 2021 | $47,000 | +213.3% | 354 | +316.5% | 0.00% | – |
| Q4 2020 | $15,000 | +50.0% | 85 | 0.0% | 0.00% | – |
| Q3 2020 | $10,000 | -28.6% | 85 | -62.7% | 0.00% | – |
| Q2 2020 | $14,000 | -64.1% | 228 | -55.8% | 0.00% | -100.0% |
| Q3 2019 | $39,000 | +69.6% | 516 | +41.0% | 0.00% | 0.0% |
| Q2 2019 | $23,000 | – | 366 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |